Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  romidepsin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 32 for your search:
Start Over
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C14012, 2011-003545-18, DRKS00004503, NL39566.068.12, NCT01482962
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02596, NABTC-0303, U01CA062399, CDR0000370817, NCI-05-C-0098, NCT00085540
A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: Ro-CHOP, NCT01280526
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ROMI-TCL-001, NCT01456039
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000068031, NCI-00-C-0123, NCI-1053, 1053, NCT00020202
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 010049, 01-C-0049, NCI-01-C-0049, NCI-1312, NCT00020436, 1312, NCT00007345
Phase II Pilot Study of FR901228 (Depsipeptide) in Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Intermediate-Grade or Follicular Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-00116, NCI-1715, 1715, NCT00042822
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00034, 12209B, CDR0000304460, N01CM62201, N01CM17102, U01CA099177, P30CA014599, UCCRC-12209B, NCI-5965, 5965, NCT00062075
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03005, NCI-5996, 0403-765, 5996, N01CM62204, P30CA013330, AECM-0403765, NCT00066638
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02571, MAYO-MC0287, NCI-5961, CDR0000349660, 5961, NCT00077194
Phase II Study of FR901228 (Depsipeptide) in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: SWOG-S0336, S0336, NCT00077337
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00027, MMC 04-02-025S, N01CM62204, AECM-02025, NYWCCC-02025, 6335, NYWCCC-0402025S, NCI-6335, DFCI-04358, NCT00084682
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02785, CALGB-30304, P30CA014236, U10CA031946, NCT00086827
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01458, 04-059, N01CM62206, CDR0000396783, MSKCC-04059, NCI-6338, 6338, NCT00098813
FR901228 in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02641, MDA-2003-0895, N01CM17003, CDR0000404163, 6369, NCI-6369, NCT00098397
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000415355, U10CA021115, ECOG-E1603, E1603, NCT00104884
A Research Study for Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FJ-228-0002, NCT00106418
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01037, CDR0000433042, CCCWFU 71103, 6319, U10CA081851, P30CA012197, NCT00112463
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GPI-06-0002, NCT00426764
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ROMI-ADVM-004, 2010-023040-32, NCT01353664
Phase I Study of Intravenous Depsipeptide for Refractory Advanced Adult Malignancies (Summary Last Modified 11/1999)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: GUMC-95066, GUMC-T95-0022, NCI-T95-0022D, T95-0022
Depsipeptide in Treating Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000065653, NCI-97-C-0135G, NCI-T95-0077, T95-0077, NCT00019318
Phase I Study of FR901228 (Depsipeptide) in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-00H0350, NCI-27, NCT00024180, 27
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 020205, 02-C-0205, NCT00037817
Start Over